Alvotech

ALVO64

High Growth

$11.84arrow_drop_down1.25%-$0.15

High Growth

ALVO64

$11.84

arrow_drop_down1.25%-$0.15

High Growth

Performance History

Key Stats
Open	$12.00
Prev. Close	$12.00
EPS	-1.85
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	11.83	12.06
52 Week Range	8.30	18.00

Ratios







EPS	-1.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Alvotech (ALVO)

Alvotech (ALVO) is a biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar medicines. The company is focused on improving patient access to affordable and effective treatments. Alvotech is committed to delivering complex biologics with the same high standards of quality, efficacy, and safety as the originator drugs. The company's mission is to provide patients with sustainable access to safe and affordable medicines on a global scale.

The stock price history of Alvotech (ALVO) shows fluctuations over time, influenced by various market factors and company-specific developments. Investors should carefully analyze these trends and consider their investment objectives and risk tolerance before making any investment decisions. It is important to note that past performance is not indicative of future results.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Robert Wessman
Headquarters: Reykjavik
Employees: 917
Exchange: NASDAQ

Keep an eye on Alvotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Alvotech's (ALVO) price per share?

The current price per share for Alvotech (ALVO) is $11.84. The stock has seen a price change of -$0.15 recently, indicating a -1.25% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Alvotech (ALVO)?

For Alvotech (ALVO), the 52-week high is $18, which is 52.03% from the current price. The 52-week low is $8.3, the current price is 42.65% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Alvotech (ALVO) a growth stock?

Alvotech (ALVO) has shown an average price growth of -3.4% over the past three years. It has received a score of 84 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Alvotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Alvotech (ALVO) stock price performance year to date (YTD)?

As of the latest data, Alvotech (ALVO) has a year-to-date price change of 4.23%. Over the past month, the stock has experienced a price change of -8.85%. Over the last three months, the change has been 0.77%. Over the past six months, the figure is -15.37%.

help

Is Alvotech (ALVO) a profitable company?

Alvotech (ALVO) has a net income of -$551.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 46.22% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $91.43M, with a revenue growth rate of 10.12%, providing insight into the company's sales performance and growth. Operating income is noted at -$354.86M. Furthermore, the EBITDA is -$104.55M.

help

What is the market capitalization of Alvotech (ALVO)?

Alvotech (ALVO) has a market capitalization of $3.57B. The average daily trading volume is 11.92, indicating the stock's liquidity and investor engagement.

News

ALVOTECH

JEFFERIES HEALTHCARE CONFERENCE

BIOSIMILAR PRODUCTS

Oct 25, 2024

Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024

ALVOTECH

JEFFERIES LONDON HEALTHCARE CONFERENCE

BIOTECH

BIOSIMILAR MEDICINES

Oct 25, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

ALVOTECH

JEFFERIES LONDON HEALTHCARE CONFERENCE

BIOSIMILAR MEDICINES

Oct 25, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech veitt aukið markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn), líftæknilyfjahliðstæðu við Stelara, til meðferðar sjúkdóma í meltingarvegi

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)